173 related articles for article (PubMed ID: 34330805)
1. Immune Checkpoint Inhibitor-Related Adverse Effects and
Schierz JH; Sarikaya I; Wollina U; Unger L; Sarikaya A
J Nucl Med Technol; 2021 Dec; 49(4):324-329. PubMed ID: 34330805
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
3. Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging.
Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
Q J Nucl Med Mol Imaging; 2022 Sep; 66(3):245-254. PubMed ID: 35612369
[TBL] [Abstract][Full Text] [Related]
4. The value of
Ayati N; Sadeghi R; Kiamanesh Z; Lee ST; Zakavi SR; Scott AM
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):428-448. PubMed ID: 32728798
[TBL] [Abstract][Full Text] [Related]
5. Interpretation of 2-[
Manson G; Lemchukwu AC; Mokrane FZ; Lopci E; Aide N; Vercellino L; Houot R; Dercle L
Eur Radiol; 2022 Sep; 32(9):6536-6544. PubMed ID: 35344061
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic impact of
Tatar G; Alçin G; Sengul Samanci N; Erol Fenercioglu Ö; Beyhan E; Cermik TF
Clin Transl Oncol; 2022 Oct; 24(10):1903-1913. PubMed ID: 35594002
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
8. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
[TBL] [Abstract][Full Text] [Related]
9. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
[TBL] [Abstract][Full Text] [Related]
10. Imaging assessment of toxicity related to immune checkpoint inhibitors.
Berz AM; Boughdad S; Vietti-Violi N; Digklia A; Dromain C; Dunet V; Duran R
Front Immunol; 2023; 14():1133207. PubMed ID: 36911692
[TBL] [Abstract][Full Text] [Related]
11. Interim [
Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
[TBL] [Abstract][Full Text] [Related]
12. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
13.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
14. Rational use of
Bisschop C; de Heer EC; Brouwers AH; Hospers GAP; Jalving M
Crit Rev Oncol Hematol; 2020 Sep; 153():103044. PubMed ID: 32673997
[No Abstract] [Full Text] [Related]
15.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
16. Is
Karlsen W; Akily L; Mierzejewska M; Teodorczyk J; Bandura A; Zaucha R; Cytawa W
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893111
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
[TBL] [Abstract][Full Text] [Related]
18. Is there a link between very early changes of primary and secondary lymphoid organs in
Seith F; Forschner A; Weide B; Gückel B; Schwartz M; Schwenck J; Othman AE; Fenchel M; Garbe C; Nikolaou K; Schwenzer N; la Fougère C; Pfannenberg C
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753543
[TBL] [Abstract][Full Text] [Related]
19. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
[TBL] [Abstract][Full Text] [Related]
20. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Castello A; Lopci E
Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
